Sanatorium profesora Arenbergera

The medical center is at the forefront of oncology research, particularly in the treatment of unresectable or metastatic NRAS mutant cutaneous melanoma. This area of study focuses on innovative therapeutic combinations to improve patient outcomes.

• Combination Therapies
• Targeted Treatments
• Survival Rate Improvement

Through rigorous clinical trials, the center is pioneering the use of novel drug combinations, such as naporafenib and trametinib, to enhance progression-free survival and overall survival rates in patients.

Specializing in recurrent or metastatic squamous cell carcinoma of the head and neck, the center is dedicated to advancing treatment protocols that significantly extend patient survival.

• Immunotherapy Integration
• Maintenance Therapies
• Survival Efficacy Studies

By integrating immunotherapies such as avelumab and cetuximab, the center is setting new standards in the management of head and neck cancers, focusing on long-term efficacy and quality of life improvements.